Global Markets Direct’s, 'Nonhematologic Malignancy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Nonhematologic Malignancy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nonhematologic Malignancy. Nonhematologic Malignancy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Nonhematologic Malignancy. - A review of the Nonhematologic Malignancy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Nonhematologic Malignancy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Nonhematologic Malignancy. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Nonhematologic Malignancy pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Nonhematologic Malignancy - Pipeline Review, H2 2013 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Nonhematologic Malignancy Overview 6 Therapeutics Development 7 An Overview of Pipeline Products for Nonhematologic Malignancy 7 Nonhematologic Malignancy Therapeutics under Development by Companies 9 Early Clinical Stage Products 10 Comparative Analysis 10 Nonhematologic Malignancy Therapeutics - Products under Development by Companies 11 Companies Involved in Nonhematologic Malignancy Therapeutics Development 12 Boehringer Ingelheim GmbH 12 Millennium Pharmaceuticals, Inc. 13 Astellas Pharma Inc. 14 Celgene Corporation 15 Nonhematologic Malignancy - Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Route of Administration 17 Assessment by Molecule Type 19 Drug Profiles 21 ixazomib citrate - Drug Profile 21 Product Description 21 Mechanism of Action 21 RandD Progress 21 pevonedistat - Drug Profile 24 Product Description 24 Mechanism of Action 24 RandD Progress 24 sirolimus albumin-bound - Drug Profile 25 Product Description 25 Mechanism of Action 25 RandD Progress 25 MLN-0128 - Drug Profile 26 Product Description 26 Mechanism of Action 26 RandD Progress 26 TAK-733 - Drug Profile 28 Product Description 28 Mechanism of Action 28 RandD Progress 28 MLN-1117 - Drug Profile 30 Product Description 30 Mechanism of Action 30 RandD Progress 30 BI-853520 - Drug Profile 31 Product Description 31 Mechanism of Action 31 RandD Progress 31 VS-4718 - Drug Profile 32 Product Description 32 Mechanism of Action 32 RandD Progress 32 ASP-9853 - Drug Profile 33 Product Description 33 Mechanism of Action 33 RandD Progress 33 Nonhematologic Malignancy Therapeutics - Drug Profile Updates 34 Nonhematologic Malignancy Therapeutics - Discontinued Products 40 Nonhematologic Malignancy Therapeutics - Dormant Products 41 Appendix 42 Methodology 42 Coverage 42 Secondary Research 42 Primary Research 42 Expert Panel Validation 42 Contact Us 43 Disclaimer 43
List of Tables
Number of Products Under Development for Nonhematologic Malignancy, H2 2013 7 Products under Development for Nonhematologic Malignancy - Comparative Analysis, H2 2013 8 Number of Products under Development by Companies, H2 2013 9 Comparative Analysis by Early Clinical Stage Development, H2 2013 10 Products under Development by Companies, H2 2013 11 Boehringer Ingelheim GmbH, H2 2013 12 Millennium Pharmaceuticals, Inc., H2 2013 13 Astellas Pharma Inc., H2 2013 14 Celgene Corporation, H2 2013 15 Assessment by Monotherapy Products, H2 2013 16 Assessment by Stage and Route of Administration, H2 2013 18 Assessment by Stage and Molecule Type, H2 2013 20 Nonhematologic Malignancy Therapeutics - Drug Profile Updates 34 Nonhematologic Malignancy Therapeutics - Discontinued Products 40 Nonhematologic Malignancy Therapeutics - Dormant Products 41
List of Figures
Number of Products under Development for Nonhematologic Malignancy, H2 2013 7 Products under Development for Nonhematologic Malignancy - Comparative Analysis, H2 2013 8 Products under Development by Companies, H2 2013 9 Early Clinical Stage Products, H2 2013 10 Assessment by Monotherapy Products, H2 2013 16 Assessment by Route of Administration, H2 2013 17 Assessment by Stage and Route of Administration, H2 2013 18 Assessment by Molecule Type, H2 2013 19 Assessment by Stage and Molecule Type, H2 2013 20
Boehringer Ingelheim GmbH Millennium Pharmaceuticals, Inc. Astellas Pharma Inc. Celgene Corporation